Avantogen Ltd (ASX: ACU) welcomes Professor Ian Frazer to the Scientific Advisory Board of Hawaii Biotech Inc. (HBI), where Avantogen own a significant portion of the total equity. Prof Frazer is a leading immunologist and the 2006 Australian of the Year. HBI is a privately held vaccine development company located in Honolulu, Hawaii. Details of the appointment, as outlined in the HBI company announcement, can be found below.
Dr William Ardrey, CEO of Avantogen commented, “The addition of Prof Ian Frazer to Hawaii Biotech is a very positive development for Avantogen’s shareholders. His appointment is seen as a validation of the technology platform as well as of the vaccines that are currently in clinical development at HBI. Previously, shareholders have seen progress with the US FDA and the West Nile Virus program. The Dengue program in conjunction with the Paediatric Dengue Vaccines Initiative (PDVI), funded by the Bill & Melinda Gates Foundation and Rockefeller Foundation, is also running according to schedule. We hope to deliver progress reports on these programs in the coming weeks.”
About Avantogen Limited: Avantogen Ltd (ASX: ACU) is developing and commercializing drugs and nutraceuticals in the fast growing oncology and vaccine markets. Following a company restructure in mid-2007, the Company has announced a number of high-value commercial licensing revenue partnerships with leading US biotechnology players, and seen strong success with its pipeline of promising proprietary products.
The Company successfully commenced re-trading on 3 October 2007, and is poised for a prosperous and promising future, for the benefit of current and future shareholders. The parent company, and its affiliates, has recently completed a number of positive, revenue transactions, which included collection of multi-million dollar upfront payments and execution of licensing documentation including future milestone payments and substantial future royalty streams.
Contact: Dr William Ardrey, CEO Kamini Rambausek Avantogen Ltd Monsoon Communications Tel: 0400 544 502 Tel: 03 9620 3333 www.avantogen.com
